Table 1 Characteristics of study sample

Age, years

58 ± 12

Male sex

44 (59%)

Body mass index, kg/m²

29.5 (26.1, 33.2)

Body surface area, m²

2.2 (2.0, 2.4)

 Breast cancer

7 (9%)

 Leukemia

23 (31%)

 Lymphoma

22 (29%)

 Multiple myeloma

13 (17%)

 Myelodysplastic syndrome

8 (11%)

 Sarcoma

2 (3%)

History of atrial fibrillation

14 (19%)

Left bundle branch block

3 (4%)

Hematocrit at the time of MUGA, %

33.0 ± 5.4

Serum creatinine at the time of MUGA, mg/dL

1.0 ± 0.7

Heart rate during MUGA, beats/min

76.9 ± 14.4

MUGA radioisotope dose, mCi

26.2 ± 1.7

MUGA LVEF, %

48.5 ± 11.5

Interval between MUGA and CMR, days

8.0 (5.5, 10.0)

CMR LV end diastolic volume, mL

167 ± 45

CMR LV end diastolic volume, indexed (mL/m²)

76.6 ± 20.0

CMR LV mass, g

121 ± 28

CMR LV mass, indexed (g/m²)

55.3 ± 11.6

CMR regional LV dysfunction

6 (8%)

CMR LVEF, %

50.0 ± 9.9